ea0029p699 | Diabetes | ICEECE2012
Vantyghem M.
, Balavoine A.
, Defrance F.
, Douillard C.
, Van Belle E.
, Foucher C.
, Gautier C.
, Kerr-conte J.
, Noel C.
, Pattou F.
Long-term benefit-risk ratio of IT remains poorly evaluated. The aim of this work was to determine the evolution of macroangiopathic complications 5 years after IT.21 out of the 36 prospectively followed islet-transplanted patients in a single center, had at least 5 years of follow-up and were included. Their initial features were: duration of C-peptide negative diabetes: 28±9years; age: 43±7years; BMI: 24±0.2 kg/m2; 8/21 kidney-transplant...